GRFS:NASDAQ
Grifols SA - ADR ADR Class B
$8.15
arrow_downward
-0.61%(-0.050) 1D
$8.14
arrow_downward
-0.12% (-0.0100)bedtimeAfter hours
Closed: Nov 20, 4:00:02 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRFS...
Open
$8.10
High
$8.23
Low
$8.08
Mkt. cap
7.30B
Avg. vol.
714.67K
Volume
848.27K
Dividend
3.22%
Quarterly dividend
$0.07
Ex-dividend date
Dec 2, 2026
P/E ratio
10.46
52-wk high
$9.77
52-wk low
$6.96
EPS
$0.78
Beta
0.75
Shares outstanding
261.42M
No. of employees
25K
Open
$8.10
High
$8.23
Low
$8.08
Mkt. cap
7.30B
Avg. vol.
714.67K
Volume
848.27K
Dividend
3.22%
Quarterly dividend
$0.07
Ex-dividend date
Dec 2, 2026
P/E ratio
10.46
52-wk high
$9.77
52-wk low
$6.96
EPS
$0.78
Beta
0.75
Shares outstanding
261.42M
No. of employees
25K
News stories
From web sources and news partners
The Motley Fool
·
54 minutes ago
The S&P 500 Is 14 for 14 After Midterm Elections. Here’s How I’d Invest Now.
Yahoo Finance
·
1 day ago
Chips suffer worst week since 2001 as the Nasdaq nears a bear market
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA - ADR ADR Class B
CEONacho Abia
Employees25K
FoundedNov 18, 1940
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitegrifols.com